NCT03335553

A Study of Experimental Medication BMS-986235 in Healthy Subjects

Completed Phase 1 Last updated 31 March 2022

What this trial tests

Phase 1 trial testing BMS-986235 in Mediators of Inflammation in 122 participants. Completed in 2 July 2021.

Timeline

15 November 2017

Primary endpoint
2 July 2021

2 July 2021

Quick facts

Lead sponsor	Bristol-Myers Squibb
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	122
Start date	15 November 2017
Primary completion	2 July 2021
Estimated completion	2 July 2021
Sites	2 locations across United States

Drugs / interventions tested

• BMS-986235 — full drug profile →
• Placebo

Conditions studied

• Mediators of Inflammation — all drugs for Mediators of Inflammation →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

Adults 18 to 55, any sex, with Mediators of Inflammation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a study of experimental medication BMS-986235 in healthy subjects.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Formyl peptide receptor type 2 agonists to kick-start resolution pharmacology.
   Perretti M, Godson C. · · 2020 · cited 61× · PMID 32954491 · DOI 10.1111/bph.15212
2. Formylpeptide receptor 2: Nomenclature, structure, signalling and translational perspectives: IUPHAR review 35.
   Qin CX, Norling LV, Vecchio EA, Brennan EP, et al · · 2022 · cited 52× · PMID 35797341 · DOI 10.1111/bph.15919
3. Selective FPR2 Agonism Promotes a Proresolution Macrophage Phenotype and Improves Cardiac Structure-Function Post Myocardial Infarction.
   García RA, Lupisella JA, Ito BR, Hsu MY, et al · · 2021 · cited 49× · PMID 34466754 · DOI 10.1016/j.jacbts.2021.07.007
4. Annexin A1 attenuates cardiac diastolic dysfunction in mice with inflammatory arthritis.
   Chen J, Norling LV, Mesa JG, Silva MP, et al · · 2021 · cited 35× · PMID 34526398 · DOI 10.1073/pnas.2020385118
5. Molecular Pharmacology of Inflammation Resolution in Atherosclerosis.
   Kotlyarov S, Kotlyarova A. · · 2022 · cited 21× · PMID 35563200 · DOI 10.3390/ijms23094808
6. Formyl peptide receptor 2 as a potential therapeutic target for inflammatory bowel disease.
   Yang WS, Wang JL, Wu W, Wang GF, et al · · 2023 · cited 18× · PMID 35840658 · DOI 10.1038/s41401-022-00944-0
7. Novel formylpeptide receptor 1/2 agonist limits hypertension-induced cardiovascular damage.
   Singh J, Jackson KL, Fang H, Gumanti A, et al · · 2024 · cited 11× · PMID 38879891 · DOI 10.1093/cvr/cvae103
8. The <i>N</i>-formyl peptide receptors: much more than chemoattractant receptors. Relevance in health and disease.
   Napolitano F, Montuori N. · · 2025 · cited 8× · PMID 40103822 · DOI 10.3389/fimmu.2025.1568629